SLC18A2 and choreatic disease: Dopamine receptor agonists have been shown to exacerbate abnormal involuntary movements in early HD patients (Newman et al., 1985), and current FDA-approved drugs to treat chorea in HD are the vesicular monoamine transporter 2 (VMAT2) inhibitors, Tetrabenazine (Huntington Study, 2006) and Deutetrabenazine (Frank et al., 2016), which reduce dopamine availability in the synapse.